Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites

Sean Ekins, Cheng Chang, Sridhar Mani, Matthew D. Krasowski, Erica J. Reschly, Manisha Iyer, Vladyslav Kholodovych, Ni Ai, William J. Welsh, Michael Sinz, Peter W. Swaan, Rachana Patel, Kenneth Bachmann

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

The pregnane X receptor (PXR) is an important transcriptional regulator of the expression of xenobiotic metabolism and transporter genes. The receptor is promiscuous, binding many structural classes of molecules that act as agonists at the ligand-binding domain, triggering up-regulation of genes, increasing the metabolism and excretion of therapeutic agents, and causing drug-drug interactions. It has been suggested that human PXR antagonists represent a means to counteract such interactions. Several azoles have been hypothesized to bind the activation function-2 (AF-2) surface on the exterior of PXR when agonists are concurrently bound in the ligand-binding domain. In the present study, we have derived novel computational models for PXR agonists using different series of imidazoles, steroids, and a set of diverse molecules with experimental PXR agonist binding data. We have additionally defined a novel pharmacophore for the steroidal agonist site. All agonist pharmacophores showed that hydrophobic features are predominant. In contrast, a qualitative comparison with the corresponding PXR antagonist pharmacophore models using azoles and biphenyls showed that they are smaller and hydrophobic with increased emphasis on hydrogen bonding features. Azole antagonists were docked into a proposed hydrophobic binding pocket on the outer surface at the AF-2 site and fitted comfortably, making interactions with key amino acids involved in charge clamping. Combining computational and experimental data for different classes of molecules provided strong evidence for agonists and antagonists binding distinct regions on PXR. These observations bear significant implications for future discovery of molecules that are more selective and potent antagonists.

Original languageEnglish (US)
Pages (from-to)592-603
Number of pages12
JournalMolecular Pharmacology
Volume72
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Binding Sites
Azoles
Imidazoles
Ligands
Xenobiotics
Hydrogen Bonding
pregnane X receptor
Drug Interactions
Constriction
Genes
Up-Regulation
Steroids
Amino Acids
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. / Ekins, Sean; Chang, Cheng; Mani, Sridhar; Krasowski, Matthew D.; Reschly, Erica J.; Iyer, Manisha; Kholodovych, Vladyslav; Ai, Ni; Welsh, William J.; Sinz, Michael; Swaan, Peter W.; Patel, Rachana; Bachmann, Kenneth.

In: Molecular Pharmacology, Vol. 72, No. 3, 09.2007, p. 592-603.

Research output: Contribution to journalArticle

Ekins, S, Chang, C, Mani, S, Krasowski, MD, Reschly, EJ, Iyer, M, Kholodovych, V, Ai, N, Welsh, WJ, Sinz, M, Swaan, PW, Patel, R & Bachmann, K 2007, 'Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites', Molecular Pharmacology, vol. 72, no. 3, pp. 592-603. https://doi.org/10.1124/mol.107.038398
Ekins, Sean ; Chang, Cheng ; Mani, Sridhar ; Krasowski, Matthew D. ; Reschly, Erica J. ; Iyer, Manisha ; Kholodovych, Vladyslav ; Ai, Ni ; Welsh, William J. ; Sinz, Michael ; Swaan, Peter W. ; Patel, Rachana ; Bachmann, Kenneth. / Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. In: Molecular Pharmacology. 2007 ; Vol. 72, No. 3. pp. 592-603.
@article{b6a8ccd2e6774d69b479613bf0f0b85d,
title = "Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites",
abstract = "The pregnane X receptor (PXR) is an important transcriptional regulator of the expression of xenobiotic metabolism and transporter genes. The receptor is promiscuous, binding many structural classes of molecules that act as agonists at the ligand-binding domain, triggering up-regulation of genes, increasing the metabolism and excretion of therapeutic agents, and causing drug-drug interactions. It has been suggested that human PXR antagonists represent a means to counteract such interactions. Several azoles have been hypothesized to bind the activation function-2 (AF-2) surface on the exterior of PXR when agonists are concurrently bound in the ligand-binding domain. In the present study, we have derived novel computational models for PXR agonists using different series of imidazoles, steroids, and a set of diverse molecules with experimental PXR agonist binding data. We have additionally defined a novel pharmacophore for the steroidal agonist site. All agonist pharmacophores showed that hydrophobic features are predominant. In contrast, a qualitative comparison with the corresponding PXR antagonist pharmacophore models using azoles and biphenyls showed that they are smaller and hydrophobic with increased emphasis on hydrogen bonding features. Azole antagonists were docked into a proposed hydrophobic binding pocket on the outer surface at the AF-2 site and fitted comfortably, making interactions with key amino acids involved in charge clamping. Combining computational and experimental data for different classes of molecules provided strong evidence for agonists and antagonists binding distinct regions on PXR. These observations bear significant implications for future discovery of molecules that are more selective and potent antagonists.",
author = "Sean Ekins and Cheng Chang and Sridhar Mani and Krasowski, {Matthew D.} and Reschly, {Erica J.} and Manisha Iyer and Vladyslav Kholodovych and Ni Ai and Welsh, {William J.} and Michael Sinz and Swaan, {Peter W.} and Rachana Patel and Kenneth Bachmann",
year = "2007",
month = "9",
doi = "10.1124/mol.107.038398",
language = "English (US)",
volume = "72",
pages = "592--603",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites

AU - Ekins, Sean

AU - Chang, Cheng

AU - Mani, Sridhar

AU - Krasowski, Matthew D.

AU - Reschly, Erica J.

AU - Iyer, Manisha

AU - Kholodovych, Vladyslav

AU - Ai, Ni

AU - Welsh, William J.

AU - Sinz, Michael

AU - Swaan, Peter W.

AU - Patel, Rachana

AU - Bachmann, Kenneth

PY - 2007/9

Y1 - 2007/9

N2 - The pregnane X receptor (PXR) is an important transcriptional regulator of the expression of xenobiotic metabolism and transporter genes. The receptor is promiscuous, binding many structural classes of molecules that act as agonists at the ligand-binding domain, triggering up-regulation of genes, increasing the metabolism and excretion of therapeutic agents, and causing drug-drug interactions. It has been suggested that human PXR antagonists represent a means to counteract such interactions. Several azoles have been hypothesized to bind the activation function-2 (AF-2) surface on the exterior of PXR when agonists are concurrently bound in the ligand-binding domain. In the present study, we have derived novel computational models for PXR agonists using different series of imidazoles, steroids, and a set of diverse molecules with experimental PXR agonist binding data. We have additionally defined a novel pharmacophore for the steroidal agonist site. All agonist pharmacophores showed that hydrophobic features are predominant. In contrast, a qualitative comparison with the corresponding PXR antagonist pharmacophore models using azoles and biphenyls showed that they are smaller and hydrophobic with increased emphasis on hydrogen bonding features. Azole antagonists were docked into a proposed hydrophobic binding pocket on the outer surface at the AF-2 site and fitted comfortably, making interactions with key amino acids involved in charge clamping. Combining computational and experimental data for different classes of molecules provided strong evidence for agonists and antagonists binding distinct regions on PXR. These observations bear significant implications for future discovery of molecules that are more selective and potent antagonists.

AB - The pregnane X receptor (PXR) is an important transcriptional regulator of the expression of xenobiotic metabolism and transporter genes. The receptor is promiscuous, binding many structural classes of molecules that act as agonists at the ligand-binding domain, triggering up-regulation of genes, increasing the metabolism and excretion of therapeutic agents, and causing drug-drug interactions. It has been suggested that human PXR antagonists represent a means to counteract such interactions. Several azoles have been hypothesized to bind the activation function-2 (AF-2) surface on the exterior of PXR when agonists are concurrently bound in the ligand-binding domain. In the present study, we have derived novel computational models for PXR agonists using different series of imidazoles, steroids, and a set of diverse molecules with experimental PXR agonist binding data. We have additionally defined a novel pharmacophore for the steroidal agonist site. All agonist pharmacophores showed that hydrophobic features are predominant. In contrast, a qualitative comparison with the corresponding PXR antagonist pharmacophore models using azoles and biphenyls showed that they are smaller and hydrophobic with increased emphasis on hydrogen bonding features. Azole antagonists were docked into a proposed hydrophobic binding pocket on the outer surface at the AF-2 site and fitted comfortably, making interactions with key amino acids involved in charge clamping. Combining computational and experimental data for different classes of molecules provided strong evidence for agonists and antagonists binding distinct regions on PXR. These observations bear significant implications for future discovery of molecules that are more selective and potent antagonists.

UR - http://www.scopus.com/inward/record.url?scp=34548308480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548308480&partnerID=8YFLogxK

U2 - 10.1124/mol.107.038398

DO - 10.1124/mol.107.038398

M3 - Article

C2 - 17576789

AN - SCOPUS:34548308480

VL - 72

SP - 592

EP - 603

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -